Author(s): Welzen ME, Brggemann RJ, Van Den Berg JM, Voogt HW, Gilissen JH,
Abstract Share this page
Abstract Posaconazole (PSZ) may be an attractive alternative for antifungal prophylaxis in children with chronic granulomatous disease. Experience with PSZ in pediatric patients is limited, and no specific dose recommendations exist. A twice daily dosing algorithm based on allometric scaling (body-weight based) for PSZ results in adequate exposure and appears to be safe in children with chronic granulomatous disease.
This article was published in Pediatr Infect Dis J
and referenced in Journal of Antivirals & Antiretrovirals